GlassScriptPhysician profile
Danny Mammo
NPI 1982053872
$149,111.79
in general payments reported to CMS, 2019-2025
17 companies · $83K in 2025
The $83K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $76.21 · 2021: $300 · 2022: $2,761 · 2023: $18K · 2024: $45K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $49K · Consulting Fee: $48K · Honoraria: $28K · Travel and Lodging: $8,973 · Food and Beverage: $6,854 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Grant: $700 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $49,335.50 |
| Consulting Fee | $48,494.49 |
| Honoraria | $28,317.50 |
| Travel and Lodging | $8,972.65 |
| Food and Beverage | $6,854.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Grant | $700.00 |
| Education | $195.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $46,207.81 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $35,530.64 | 2022-2025 | Xipere, Stellaris Elite, Surgical Misc |
| Alimera Sciences, INC. | $16,762.62 | 2022-2024 | Iluvien, Yutiq |
| Ani Pharmaceuticals, INC. | $12,506.02 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Genentech USA, INC. | $9,145.61 | 2022-2025 | Vabysmo |
| Abbvie INC. | $5,536.29 | 2023-2025 | |
| Eyepoint US, INC. | $5,050.53 | 2022-2024 | |
| Regeneron Pharmaceuticals, INC. | $4,319.64 | 2023-2025 | Eylea Hd, Eylea |
| Carl Zeiss Meditec USA, INC. | $3,773.04 | 2025 | Cirrus Hd-Oct, Callisto Eye, Cirrus 6000 With Angioplex |
| Neurotech Pharmaceuticals, INC. | $3,204.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $3,197.58 | 2023-2024 | Eylea, Eylea Hd |
| Harrow Eye, LLC | $2,931.08 | 2025 | Triesence |
| Ocular Therapeutix, INC. | $436.94 | 2023-2025 | Dextenza |
| Alcon Vision LLC | $433.78 | 2019-2025 | Unity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.09 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21.52 | 2020 | |
| Beaver-Visitec International, INC. | $13.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Mammo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.